- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00260078
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children
Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Because all of the available non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) are metabolized by and affect hepatic cytochrome enzymes, combinations of two or more of these drugs produce complex pharmacokinetic (PK) interactions. However, little data exist regarding PK of anti-HIV drug combinations in the pediatric population. The purpose of this study is to assess steady-state PK of the following anti-HIV regimens: TDF and EFV or NVP; TDF and DRV with or without EFV; and TDF and RTV with or without EFV. In addition, this study will evaluate how age, length of treatment, adverse effects, and genes affect children's response to different anti-HIV combinations.
This study will last between 1 and 7 weeks. Participants in this study will be grouped based on the treatment regimen they are receiving or about to initiate. There are three groups in this study. Group D participants will receive TDF and EFV or NVP; Group E participants will receive TDF and DRV with or without EFV; and Group F participants will receive TDF and RTV with or without EFV. The inclusion of EFV or NVP will be dependent on each participant's prescribed regimen. Participants within each group will be stratified by age and how long they have been receiving their anti-HIV regimens. Antiretrovirals will not be provided by this study.
Most participants will have two study visits. The first visit will occur at study entry. Medical history, a physical exam, and blood collection will occur. The second visit will occur within 35 days of study entry and will take approximately 24 hours. Blood collection for PK studies, a physical exam, and medical history will be done at this visit. Urine collection will occur at all visits for female participants.
Participants will undergo PK testing at least 14 days after initiating their study regimens. Participants will be given a dose of their anti-HIV medications with food. A blood sample will be taken before dosing. Blood samples will also be taken at 1, 2, 4, 6, 8, 12, and 24 hours after dosing. Participants in Groups E and F may need to repeat PK testing within 6 weeks of initial PK testing at the discretion of the investigator.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
San Juan, Puerto Rico, 00936
- San Juan City Hosp. PR NICHD CRS
-
San Juan, Puerto Rico, 00935
- University of Puerto Rico Pediatric HIV/AIDS Research Program CRS
-
-
-
-
California
-
Alhambra, California, Verenigde Staten, 91803
- Usc La Nichd Crs
-
La Jolla, California, Verenigde Staten, 92093-0672
- University of California, UC San Diego CRS
-
Long Beach, California, Verenigde Staten, 90806
- Miller Children's Hosp. Long Beach CA NICHD CRS
-
Torrance, California, Verenigde Staten, 90502
- Harbor UCLA Medical Ctr. NICHD CRS
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06106
- Connecticut Children's Med. Ctr.
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33136
- Pediatric Perinatal HIV Clinical Trials Unit CRS
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Rush Univ. Cook County Hosp. Chicago NICHD CRS
-
Chicago, Illinois, Verenigde Staten, 60614-3393
- Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- Univ. of Maryland Baltimore NICHD CRS
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins Univ. Baltimore NICHD CRS
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Children's Hosp. of Boston NICHD CRS
-
Springfield, Massachusetts, Verenigde Staten, 01199
- Baystate Health, Baystate Med. Ctr.
-
Worcester, Massachusetts, Verenigde Staten, 01605
- WNE Maternal Pediatric Adolescent AIDS CRS
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Children's Hospital of Michigan NICHD CRS
-
-
New Jersey
-
Newark, New Jersey, Verenigde Staten, 07103
- Rutgers - New Jersey Medical School CRS
-
-
New York
-
Bronx, New York, Verenigde Staten, 10461
- Jacobi Med. Ctr. Bronx NICHD CRS
-
Brooklyn, New York, Verenigde Staten, 11203
- SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
-
New York, New York, Verenigde Staten, 10016
- Nyu Ny Nichd Crs
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- DUMC Ped. CRS
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38105-3678
- St. Jude Children's Research Hospital CRS
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Seattle Children's Hospital CRS
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Note: The original Groups A, B, and C have been removed, and Groups D, E, and F have been added per protocol amendment dated 11/16/07.
Inclusion Criteria:
- HIV infected
- Currently receiving or about to initiate one of the following anti-HIV regimens: TDF with EFV or NVP, TDF and DRV/r with or without EFV, or TDF with ATV/r with or without EFV
- Body surface area at least 0.85 m2
- Parent or guardian willing and able to provide signed informed consent
- Willing to use acceptable forms of contraception
Exclusion Criteria:
- Liver disease that may affect the metabolism of study drugs
- Certain abnormal laboratory values
- Require certain medications
- Treatment with any anti-HIV or nonantiretroviral drug that could interact with drugs under PK study in the 14 days prior to study entry
- Any clinical or laboratory toxicity of Grade 4 or higher at screening. More information on this criterion can be found in the protocol.
- Pregnant or breastfeeding
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: D
TDF and EFV or NVP throughout study
|
Dosage dependent on participant
Andere namen:
Dosage dependent on participant
Andere namen:
300 mg orally daily
Andere namen:
Intensive PK study will occur at least once.
This will require a 24-hour inpatient visit.
Andere namen:
|
Experimenteel: E
TDF and DRV with or without EFV throughout study
|
Dosage dependent on participant
Andere namen:
300 mg orally daily
Andere namen:
Intensive PK study will occur at least once.
This will require a 24-hour inpatient visit.
Andere namen:
300 mg or 600 mg orally twice daily
Andere namen:
50 mg or 100 mg orally twice daily
Andere namen:
|
Experimenteel: F
TDF and ATV and RTV with or without EFV throughout study
|
Dosage dependent on participant
Andere namen:
300 mg orally daily
Andere namen:
Intensive PK study will occur at least once.
This will require a 24-hour inpatient visit.
Andere namen:
50 mg or 100 mg orally twice daily
Andere namen:
200 mg to 400 mg orally daily
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Predosage concentration (C0 and C12) and area under the concentration-time curve (AUC)
Tijdsspanne: Over the dosing interval
|
Over the dosing interval
|
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Jennifer King, PharmD, Department of Pharmacology and Toxicology, University of Alabama at Birmingham
- Studie stoel: Ram Yogev, MD, Section of Pediatrics and Maternal HIV Infection, Children's Memorial Hospital, Northwestern University Medical School
Publicaties en nuttige links
Algemene publicaties
- Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. doi: 10.1128/AAC.00761-07. Epub 2007 Nov 19.
- Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005 Dec;116(6):e846-54. doi: 10.1542/peds.2005-0975. Epub 2005 Nov 15.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- RNA-virusinfecties
- Virusziekten
- Infecties
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- Ziekten van het immuunsysteem
- HIV-infecties
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Reverse Transcriptase-remmers
- Nucleïnezuursyntheseremmers
- Enzymremmers
- Anti-hiv-middelen
- Antiretrovirale middelen
- Proteaseremmers
- Cytochroom P-450 CYP3A-remmers
- Cytochroom P-450 enzymremmers
- Cytochroom P-450 enzyminductoren
- Cytochroom P-450 CYP3A-inductoren
- HIV-proteaseremmers
- Virale proteaseremmers
- Cytochroom P-450 CYP2B6-inductoren
- Cytochroom P-450 CYP2C9-remmers
- Cytochroom P-450 CYP2C19-remmers
- Tenofovir
- Nevirapine
- Ritonavir
- Darunavir
- Atazanavirsulfaat
- Efavirenz
Andere studie-ID-nummers
- P1058
- 10050 (Register-ID: DAIDS-ES)
- PACTG 1058
- IMPAACT P1058
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op HIV-infecties
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthWervingHiv | HIV-testen | Hiv-koppeling naar zorg | HIV-behandelingVerenigde Staten
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun en andere medewerkersOnbekendHiv | HIV-niet-geïnfecteerde kinderen | Kinderen blootgesteld aan HIVKameroen
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationVoltooidPartner hiv-testen | HIV-counseling voor koppels | Paar communicatie | HIV-incidentieKameroen, Dominicaanse Republiek, Georgië, Indië
-
University of MinnesotaIngetrokkenHIV-infecties | Hiv/aids | Hiv | AIDS | Aids/Hiv probleem | AIDS en infectiesVerenigde Staten
-
Erasmus Medical CenterNog niet aan het wervenHIV-infecties | Hiv | HIV-1-infectie | HIV I-infectieNederland
-
University of Maryland, BaltimoreIngetrokkenHiv | Niertransplantatie | HIV-reservoir | CCR5Verenigde Staten
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... en andere medewerkersWervingHiv | HIV-testen | Koppeling aan zorgZuid-Afrika
-
CDC FoundationGilead SciencesOnbekendHIV Pre-expositie profylaxe | Hiv-chemoprofylaxeVerenigde Staten
-
Hospital Clinic of BarcelonaVoltooidIntegrase-remmers, HIV; HIV PROTEASE INHIBSpanje
-
National Taiwan UniversityWerving
Klinische onderzoeken op Efavirenz
-
Institut BergoniéVoltooidNon-Hodgkin-lymfoom | Vaste tumorenFrankrijk
-
St Stephens Aids TrustViiV HealthcareOnbekend
-
University Hospital, Basel, SwitzerlandUniversity of BaselVoltooidBiologische beschikbaarheid | Amorfe vaste dispersiesZwitserland
-
Shanghai Public Health Clinical CenterNog niet aan het wervenHIV-infecties | Tuberculose
-
Herlev HospitalFlexdialysis ApSVoltooid
-
Peking Union Medical College HospitalOnbekendHiv/aids | Geestelijke beperkingChina
-
Yale UniversityBeëindigdHemodialyse | HypotensieVerenigde Staten
-
Center for Clinical Pharmacology Research Bdbeq...University of the Republic, UruguayVoltooid
-
Kirby InstituteVoltooid
-
University Medicine GreifswaldVoltooidFarmacokinetiek | Farmacodynamiek | Geneesmiddelinteracties | Intestinale Transporter-expressieDuitsland